Emilio Ragosa

Securities Offerings

• IPOs for several biotech companies, as well as many underwritten follow-on public offerings
• Several biotech companies with their recent PIPE deals, RDOs, ATM and equity-line offerings
• Several multinational pharma companies in connection with their strategic investments in US public companies
• A medical device company in a reverse merger, now commonly referred to as an alternative public offering
• Several funds in PIPEs and RDOs
• Underwriters in a specialty pharma IPO

Mergers and Acquisitions

• A private biotech company in its sale to a large pharma company for up to US$7 billion
• Combination of a public biotech company client with private biotech and subsequent up-listing on stock exchange
• An Italian specialty pharma company with its acquisition of a US public specialty pharma company
• A public biotech company in its sale to strategic buyer
• A public company in its sale to private equity firm
• A public clinical research organization in several private acquisitions of e-clinical companies
• A public clinical research organization in a public tender offer of a public EDC company
• Multiple private tech and biotech companies in their critical sale transactions

Private Placements

• Private tech and biotech companies with their successful angel and venture financings
• Venture capital firms and other funds with their investments in tech and biotech companies
• Pension funds with investments in private companies

Chambers USA

• Band 3, New Jersey Corporate/M&A (2019-2024)

The Legal 500 United States

• Recommended, M&A Middle-Market ($500M-999M) (2019)
• Recommended, Venture Capital & Emerging Companies (2018-2019)

Additional Awards

• Selected as Winning Deal Team – Cross-border Turnaround Deal of the Year, Global M&A Network (2021) 
• Life Sciences Star: Finance and Transactional, LMG Life Sciences Guide (2016-2017)
• 40 Under 40, New Jersey Law Journal (2010)

^{For more information, pursuant to New Jersey Lawyer Advertising guidance, please click here.}

• BioNJ C-Suite Summit - "Chasing Breakthrough Innovation in a Time of Uncertainty,” October 6, 2023
• BioNJ Virtual C-Suite Summit - "Transitioning to the 'Next Normal': Biopharma’s Role in Addressing the COVID-19 Crisis and What’s Next," October 14, 2021
• "NYVCA FinTech Rising Summit 2017," October 11, 2017
• "NACD Princeton Chapter Presentation – An Activist Director: Good or Bad for Your Board?," April 21, 2016
• "The Generational Disruption of Corporate America," NACD New Jersey Chapter, October 21, 2015